Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Active substance : clopidogrel
Active substance : phosphate
Active substance : aspirine
Active substance : doxazosine
Topics : Health economics
Topics : Urination disorders
Topics : Urologic diseases
Producer : inconnu
Type : Drugs, devices and medical acts
Type : Health technology assessment

Topic

Economics and public health (1)
Plus ...
- Health economics (1)
Diagnostic and therapeutic techniques (1)
Plus ...
- Surgical procedures (1)
- Plus ...
  - Urogenital surgery (1)
Diseases and conditions (1)
Plus ...

Drugs, devices and medical acts (1)
Plus ...
- Health technology assessment (1)

inconnu (1)
industriels (1)

Français (1)

Active substance

aluminium (1)
aspirine (1)
clopidogrel (1)
doxazosine (1)
lithium (1)
mannitol (1)
phosphate (1)
potassium (1)
silodosine (1)
tamsulosine (1)

Drugs, devices and medical acts

Première page
Page précédente
/ 1
Page suivante
Dernière page

Sorted by :Relevance

Title
Date

Laser treatment of lower urinary tract symptoms associated with benign prostatic

Health technology assessment - Posted on 12/12/2013

Add to my selection

Première page
Page précédente
/ 1
Page suivante
Dernière page
10 par pages

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

zyT5ckGQV9cdR9T8